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Abstract
Background: A highly effective vaccine against Plasmodium falciparum malaria should induce potent, strain transcending
immunity that broadly protects against the diverse population of parasites circulating globally. We aimed to identify vaccine
candidates that fulfill the criteria.
Methods:We have measured growth inhibitory activity of antibodies raised to a range of antigens to identify those that can
efficiently block merozoite invasion for geographically diverse strains of P. falciparum.
Results: This has shown that the conserved Region III-V, of the P. falciparum erythrocyte-binding antigen (EBA)-175 was able
to induce antibodies that potently inhibit merozoite invasion across diverse parasite strains, including those reliant on
invasion pathways independent of EBA-175 function. Additionally, the conserved RIII-V domain of EBA-140 also induced
antibodies with strong in vitro parasite growth inhibitory activity.
Conclusion: We identify an alternative, highly conserved region (RIV-V) of EBA-175, present in all EBA proteins, that is the
target of potent, strain transcending neutralizing antibodies, that represents a strong candidate for development as a
component in a malaria vaccine.
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Introduction
The millennium development goals, set 13 years ago by the
United Nations, set a target to halt and begin to reverse the spread
of malaria, tuberculosis and HIV by 2015. Coordinated global
efforts to roll out insecticide-treated bed nets and improve
combination drug therapies have gained significant ground with
malaria control measures leading to a reduced global burden of
disease and mortality figures have dropped substantially in many
areas over the past decade [1]. However, reaching the goal of
malaria elimination, and in the longer term its eradication, will
require a highly efficacious vaccine.
Immunity that targets the circulating asexual stages of
Plasmodium falciparum, the causative agent of the most virulent
form of human malaria, is the basis of protection from malaria in
endemic settings [2–4], indicating that a vaccine targeting this
stage of the parasite life cycle could provide immunity in
susceptible individuals. One favored strategy towards such a
vaccine would be to induce immunity that targets the specific
process of erythrocyte entry by the blood stage merozoite [5] thus
preventing the cycles of intracellular parasite growth and
multiplication. The targets of naturally acquired immunity that
might facilitate such a strategy, however, are poorly understood.
The process of invasion is mediated by parasite adhesins
secreted from the apical region of the infectious merozoite, which
bind to receptors on the erythrocyte surface, initiating entry.
Plasmodium spp. have evolved 2 major super-families of these
adhesins, the Erythrocyte-Binding Ligands (EBLs) and the
Reticulocyte Binding Ligands (RBLs), that in P. falciparum confer
the ability to use alternate erythrocyte receptors [6–8]. These
allow the parasite to access a greater range of host erythrocytes, as
well as the ability to circumvent potentially damaging host
immune responses (reviewed in [9]). Indeed, in endemic regions,
antibodies against EBL and RBL proteins are commonly found in
malaria-exposed individuals and have been associated with
parasite growth inhibition and protection from clinical malaria
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[10–12] strongly supporting their development towards a vaccine.
Whilst individually dispensable for parasite growth in vitro, it is
clear that parasites require a minimal repertoire of EBL/RBL
function to successfully invade [13].
The first identified member of the EBL family, and the best
characterized of this group of parasite invasion ligands, is the
Erythrocyte Binding Antigen 175 (EBA-175), which binds to sialic
acid residues on Glycophorin A, the most abundant protein on the
erythrocyte surface [14,15]. Expressed in the late schizont, EBA-
175 is a type-1 transmembrane protein that is housed in the
micronemes of the apical complex in merozoites [16,17]. Around
the time of merozoite egress, the micronemes discharge their
contents at the apical tip whereupon EBA-175 becomes embedded
in the parasite plasma membrane, its extracellular domains
exposed to the bloodstream. This exposure occurs ‘‘just in time’’
for binding to erythrocyte receptors following initial contact and
reorientation of the merozoite that precedes active invasion.
However, it is not known whether EBA-175 exists on the
merozoite surface as a single entity, or as part of a larger complex
of parasite proteins that interact with the erythrocyte surface. This
might involve coordination with other EBL proteins, such as EBA-
140 (also known as BAEBL), which binds Glycophorin C, [18–20]
and facilitates an additional erythrocyte invasion pathway.
The protein structure of EBA-175, and that of all members of
the EBL family, is based on the canonical structure defined for the
Duffy-Binding Ligand of P. vivax [21]. This comprises six
extracellular regions (I-VI) followed by a transmembrane domain
and a cytoplasmic tail. Common to all EBL proteins are the
cysteine-rich domains, regions II and VI. In the P. falciparum EBA
proteins (EBA-175, 2140, and 2181), RII is comprised of a
tandem Duffy Binding Like (DBL) domain`, with the repeats
termed F1 and F2 respectively. Regions III-V (RIII-V) of EBA-175
specifically is dimorphic, with all parasite strains encoding either a
C or F allelic haplotype`, based on the original identification from
Camp and FCR3 strains [22]. No functional role has yet been
identified for this region.
Since all EBL proteins bind erythrocytes through the DBL
containing domain [23,24], vaccine development has focused on
RII. In EBA-175 RII has been shown to bind to Glycophorin A
both as a single DBL domain [25] and when both DBL domains
are present, with the latter shown to interact with sialic acid on
Glycophorin A via a molecular handshake [26]. Antibodies against
this domain block receptor binding and, to an extent, inhibit
invasion in vitro [27,28]. However, RII is also highly polymorphic,
showing strong evidence for being under immune selection to
maintain genetic diversity in parasite populations [29]. From this
perspective, it can therefore be argued that RII may not be an
optimal choice for vaccine development, because of the inherent
allele-specific nature of a vaccine-induced immune response to this
domain.
Among the RBL superfamily in P. falciparum, PfRh2a/b and
PfRh5 each show promise as potential blood stage vaccine
candidates [13,30–33]. PfRh2a/b is a tandem duplicated gene
encoding two large proteins that are identical through almost 90%
of their sequence, but diverge in the C-terminus [34]. Each binds
to an unidentified receptor on erythrocytes through a region in the
protein N-terminus [35]. Like EBA-175, there is evidence that
Rh2b plays an important role in invasion in some parasite strains
[36] and that it is a target of protective immunity to malaria [37].
PfRh5 is unique among P. falciparum EBL and RBL superfamily
members in that it does not have a trans-membrane domain and is
refractory to genetic deletion in every parasite strain tested
[30,31].
Using knowledge of the alternative invasion pathways used by
independent P. falciparum strains as a first step in identifying
candidates for further vaccine development, we expressed eight
blood stage antigens from proteins with known roles in erythrocyte
invasion, raised antibodies against these antigens, and tested the
ability of these antibodies to induce growth-inhibitory responses.
We identify EBA-175 RIII-V, as the best performing antigen in
this study. As a conserved antigen that induces potent cross strain
neutralizing antibodies we propose further development of this
domain as a component in a future malaria vaccine.
Materials and Methods
Ethics Statement
The culture of P. falciparum parasites using donated blood and
serum from the Australian Red Cross Society has been approved
by The Walter and Eliza Hall Institute Human Ethics Committee
(HEC 86/17).
Antibody generation
Purified EBA175 R2 antigen was kindly provided by Science
Applications International Corporation (SAIC) and the PfRh2 N-
terminal fragment (15.1) expression construct has been published
previously [35]. Sequences encoding the other antigens (Table S1)
were codon-optimized for expression in E. coli and synthesized by
Genscript. 3D7 EBA175 RIII-V, W2mef EBA175 RIII-V and
Rh2a/b C terminal Ag were cloned into the pET-45b (+) vector
(Novagen) using Bam HI and Xho I restriction sites to produce
recombinant proteins with an N-terminal hexa-His tag. EBA175
RIV-V and 3D7 EBA175 F2-RV were cloned into the pET303/
CT-His vector (Invitrogen) to produce recombinant proteins with
a C-terminal hexa-His tag. Each plasmid was transformed into
BL21 E. coli and His-tagged recombinant proteins were purified
from soluble lysate by affinity purification on Ni- Sepharose 6 Fast
Flow resin (GE Healthcare). Both 3D7 and W2mef EBA175 III-V
proteins were further purified by FPLC. Rabbits were immunized
with 225 mg and mice with 50 mg of antigen in Freund’ complete
adjuvant and were boosted at day 35 and day 70 with the same
amount of antigen in Freund’s incomplete adjuvant. Blood
samples were taken at days 33, 68 and 103. Rabbit immunoglob-
ulin was purified on Protein A Sepharose and buffer exchanged
into PBS then concentrated to 20 mg/ml using Amicon Ultra
centrifugal filters (Millipore).
Parasite culture
P. falciparum asexual parasites were maintained in blood group
O+ human erythrocytes at 4% hematocrit in RPMI-Hepes
supplemented with 5% AlbumaxII (Gibco) and 5% heat denatured
human serum.
Immunoblotting
Proteins from synchronized early ring stage parasite culture
supernatant were separated on 3–8% Tris-acetate SDS-polyacryl-
amide gels (Invitrogen) and transferred onto nitrocellulose
(Invitrogen). Proteins were detected using rabbit serum primary
antibody and horseradish peroxidase-conjugated goat anti-rabbit
IgG secondary antibody (Dako). Blots were processed with an
enhanced chemiluminescence system (ECL-Amersham).
Assessment of antibody responses by cytometric bead
array (CBA)
BD CBA Functional Beads (BD Bioscience, San Diego, CA,
USA) of different non-overlapping fluorescence emission intensi-
Conserved Candidate Antigen for a Malaria Vaccine
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ties were covalently coupled to P. falciparum recombinant proteins
following the manufacturer’s protocol. Briefly, 75 ml of selected
micro-beads were sonicated for 1 min and then incubated with
1.9 ml of 1 M Dithiothreitol for 1h at 22uC with agitation. The
beads were then washed 3 times and resuspended in 20 ml of
Coupling Buffer (BD Bioscience). Prior to conjugation, 90 mg of P.
falciparum proteins diluted at a final concentration of 1 mg/ml were
activated by incubation with 2 ml of Sulfosuccinimidyl 4-N-
maleimidomethyl cyclohexane 1-carboxylate (2 mg/ml) for 1 h.
The protein mixture was then run through a buffer exchange spin
column (Bio-Rad) pre-equilibrated with Coupling Buffer. The
activated protein was added to the washed micro-beads and
allowed to conjugate for 1 h at 22uC with agitation. Two ml of N-
Ethylmaleimide (2 mg/ml) were added and the mixture was
incubated for another 15 min. The beads were then washed,
resuspended in 0.5 ml of Storage Buffer (BD Bioscience) and kept
at 4uC, protected from the light until use.
For assessment of antibody responses, 1 ml of conjugated micro-
beads was diluted in 50 ml of Washing Buffer (BD Bioscience)
containing different dilutions of rabbit antibodies or non-immune
rabbit sera. The antibodies (triplicates) were incubated for 30 min
at 22uC, washed and then incubated with an anti-rabbit-IgG PE-
conjugated antibody (BD, Bioscience). After washing, the samples
were acquired using an LSR Fortessa analyzer (Becton Dickinson,
New Jersey, USA). Analysis was performed using FlowJo software.
The average mean fluorescent intensity (MFI) of non-immune
serum samples +2SD was used as a cut-off value for calculation of
end-point titres.
Growth Inhibition Assay
A Growth Inhibition Assay (GIA) protocol was modified from a
previously described method [38]. Briefly, 10 ml of trophozoite
stage parasites were added to 35 ml of erythrocytes at 2%
hematocrit in 96 well round bottom microtitre plates (Falcon) at
either 0.5% parasitemia for one cycle of growth or 0.1%
parasitemia for two cycles of growth then 5 ml of IgG or serum
was added to each well. For two cycle assays, cultures were
supplemented with 10 ml of media after 48 hours.
After incubation for either 48 hours (one cycle of growth) or
90 hours (two cycles of growth) each well was fixed at room
temperature for 30 minutes with 50 ml of 0.25% glutaraldehyde
(ProSciTech) diluted in PBS. Following centrifugation at
1200 rpm for 2 minutes, supernatants were discarded and
trophozoite stage parasites were stained with 50 ml of 5X SYBR
Green (Invitrogen) diluted in PBS. The parasitemia of each well
was determined by counting 50,000 cells by flow cytometry using a
Cell Lab Quanta SC – MPL Flow Cytometer (Beckman Coulter).
Growth was expressed as a percentage of the parasitemia obtained
using a pre-immune serum or IgG control. All samples were tested
in triplicate.
GIA assays conducted at the MVI Reference Laboratory at
NIH were performed as described previously [39]. This one-cycle
assay was performed at a final IgG concentration of 0.016–2 mg/
ml against the 3D7 P. falciparum clone.
Estimation of IC50
The IC50 for each inhibitory antibody in growth inhibition
assays was determined using Graphpad PRISM (Graphpad
Software) following the recommended protocol for non-linear
regression of a variable slope, four parameter, log(inhibitor) vs
response curve.
Inhibition of Invasion Assay
The inhibitory activity of antibodies against merozite invasion
was directly determined using viable P. falciparum merozoites made
from the D10-PfPHG line [40] as previously described [41].
Briefly, tightly synchronized late stage parasites (40–44 hours post
invasion) were magnet purified away from uninfected RBCs and
incubated with the protease inhibitor trans-Epoxysuccinyl-L-
leucylamido (4-guanidino) butane (E64) for 6 hours. After
centrifugation and resuspension in RPMI-HEPES the E64 treated
schizonts were isolated by filtration through a 1.2 mm syringe filter
(Acrodisc 32 mm, Pall). Purified merozoites (22.5 ml) were
incubated with inhibitory antibodies (2.5 ml) for 10 minutes at
37uC. Uninfected RBCs (0.5% final) were then added and the
culture agitated at 400 rpm for 10 minutes. Newly invaded ring
stage parasitemia was assessed by flow cytometry (FACSCalibur)
after 1 hour with the addition of 5 mg/ml ethidium bromide (no
wash). Flow cytometry data was analyzed using Flow Jo (Tree Star
Inc.) and ring stage parasite populations were counted using an Fl-
1 high (GFP) and Fl-2 low (EtBr) gate.
Immunofluorescence Microscopy
W2mef and W2mef175-Cterm truncation parasites were
prepared as E-64 (trans-Epoxysuccinyl-L-leucylamido (4-guani-
dino) butane)-treated schizonts (ETSs) or invading merozoites
[41]for immunofluorescence assay [42], and imaged using wide
field deconvolution microscopy, as described previously [43].
Antibodies were diluted as follows: mouse anti-EBA175 RIII-V
MAb 48/09-10F9-8-3 (1:300), rabbit anti-EBA140 R1123 (1:300),
rabbit anti-AMA1 (1:250) [17], rabbit anti-RON4 (1:250) [44].
Goat anti-mouse and rabbit Alexa FluorH 488 and 594 labeled
secondary antibodies (Molecular Probes) were diluted 1:500.
Zeiss Axiovision release 4.8 software (Zeiss) was used for fast-
iterative deconvolution. General image processing was undertaken
using ImageJ [45] and Adobe Photoshop CS5 software.
Results
Production and Immunization of Vaccine Candidate
Antigens
A comparative study was undertaken to assess the relative
potential of various malaria proteins, with known roles in
erythrocyte invasion, for their ability to induce strain-independent
inhibition of P. falciparum invasion. Eight antigens selected from 3
different P. falciparum proteins were expressed and purified for
rabbit immunization studies (Fig. 1, Table S1). Two different
regions of PfRh2 were expressed: a small N-terminal fragment
recently identified as a minimal erythrocyte receptor-binding
region and target of antibodies that inhibit merozoite invasion of
erythrocytes [35] (Fig. 1B lane 1); and a larger fragment that in
combination with EBA-175 antibodies enhanced growth inhibito-
ry activity [13] (Fig 1B lane 2). Clinical grade EBA-175 Region II
from the 3D7 strain (Fig. 1B lane 3) expressed in Pichia pastoris was
kindly provided by Science Applications International Corpora-
tion (SAIC). Five other EBA-175 antigens were expressed in E. coli;
and purified from the soluble fraction without refolding (Fig. 1B
lanes 4–7). These represented both dimorphic alleles of RIII-V,
RIV-V, and F2-RV from 3D7. EBA-140 RIII-V was also included
in this antigen comparison (Fig. 1B lane 8).
Antigen structural integrity was confirmed by testing recombi-
nant proteins in erythrocyte-binding assays where appropriate
(Fig. 1C), incorporating neuraminidase treatment to remove sialic
acid residues from surface receptors. EBA-175 RII bound
erythrocytes in a sialic acid-dependent manner as expected.
EBA-175 F2-RV (Fig. 1C) and both EBA-175 and EBA-140 RIII-
Conserved Candidate Antigen for a Malaria Vaccine
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Figure 1. Antibodies raised in rabbits against recombinant P. falciparum invasion ligands specifically recognize native parasite
antigens. A: Schematic of P. falciparum invasion ligands used to generate antigens for immunization. Black bars below the schematic structures
indicate the regions of expressed recombinant proteins. Numbers indicate the lanes on the coomassie gel shown in fig. 1B. B: Antigenic fragments of
invasion-related proteins were expressed and purified for rabbit immunization. Immunogens are shown here on SDS-PAGE. (1) Rh2 N-terminal
fragment (2) Rh2 C-terminal fragment (3) EBA-175 Region 2 (4) EBA-175 Region 3-5 3D7 (5) EBA-175 RIII-V W2mef (6) EBA-175 RIV-V (7) EBA-175 F2-R5
(8) EBA-140 RIII-V. Proteins were stained with coomassie blue. C: Recombinant Region II of EBA-175 binds to erythrocytes in a sialic-dependent
manner. Recombinant proteins EBA-175 F2-RV and RII were tested for binding to erythrocytes. Lanes 1 & 4 show protein pre-assay; 2 & 5, binding to
untreated erythrocytes; Lanes 3 & 6, binding to neuraminidase-treated erythrocytes. D: Rabbit antibodies raised to recombinant antigens specifically
recognize native parasite proteins. 1–8 correspond with antigens as described in Fig. 1A. Lanes as follows: 3D7 wild type (a), 3D7D175 KO (b), W2mef
(c), W2mefD175 KO (d), FCR3 wild type (e), 3D7D140 KO (f).
doi:10.1371/journal.pone.0072504.g001
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V did not bind erythrocytes as expected (data not shown). To
confirm recognition of native parasite proteins, sera were tested for
reactivity against post-invasion culture supernatants or schizont
lysates of various P. falciparum strains by western blot. All sera
recognized native parasite proteins and were antigen specific
(Fig. 1D). High titres of antibody were induced against all antigens,
with endpoint titration of IgG ranging between 1/1,280,000 and
1/10,240,000 (Table 1).
EBA-175 Region III-V antibodies potently inhibit
geographically and genotypically diverse parasite strains
A previous study indicated that rabbit immune serum against
EBA-175 RIII-V (derived from the 3D7 strain) were around 20%
inhibitory by growth inhibition assay (GIA) against the homolo-
gous parasite strain [13]. In that study, the antigen was produced
in E. coli as an N-terminally tagged GST fusion protein. In order to
comply with FDA regulations for human vaccine trials, we re-
expressed this antigen as a fusion protein with a 6-HIS tag.
Surprisingly, and in contrast with previous results using the same
antigen as a GST-tagged fusion protein, high GIA activity of
around 80% was observed against the 3D7 homologous parasite
strain with IgG from rabbits immunized with the 6-His-tagged
antigen. This remained potent at very low IgG concentrations with
an IC50 for total IgG against RIII-V of 9mg/ml as calculated by
interpolation on the x-axis of the point at which GIA =50%
(Fig. 2A).
Because of the dimorphic nature of EBA-175 RIII-V, rabbit
IgG was also generated against W2mef RIII-V representing C-
type alleles of this protein (3D7 belonging to the F-type) to
determine whether antigenic diversity between the two allelic types
affected cross-strain protection. Surprisingly, both antibodies
inhibited parasite growth of homologous and heterologous parasite
strains by around 80% compared with control IgG, at antibody
concentrations ranging from 0.5 to 2 mg/ml (Fig. 2B & C). The
inhibitory capacity of antibodies raised against W2mef RIII-V
appeared to titrate down to zero GIA activity at 16 mg/ml
(Fig. 2C), whereas anti-3D7 RIII-V antibodies showed more than
60% inhibition against 3D7 and FCR3 parasites at a concentra-
tion of 16 mg/ml. W2mef parasites appeared to be less susceptible
to growth inhibition compared to the other two strains, but
nonetheless were still inhibited by 70% compared with control IgG
at a concentration of 0.5 mg/ml (Fig. 2B). The inhibitory activity
of the anti-EBA-175 RIII-V IgG was entirely specific to EBA-175,
as no inhibition was observed against transgenic EBA-175 knock-
out parasites. We tested the invasion inhibitory activity of
antibodies raised against EBA-175 RIII-V (3D7) using purified
P. falciparum merozoites and confirmed that these antibodies are
potent inhibitors of merozoite invasion (Fig. 2D). To control for
any specific inhibitory response restricted to rabbits, we also
immunized mice with EBA-175 RIII-V. GIA confirmed that
pooled mouse serum (not IgG purified) was also highly inhibitory
to parasite growth in an antigen-specific and titratable manner
against three parasite strains (Fig. 2E).
Region IV-V of EBA-175 contains major epitopes for
neutralizing antibodies
Having identified evidence for cross-strain immunity arising
from RIII-V, we extended GIA analysis at a fixed concentration of
1 mg/ml against a panel of 13 independent P. falciparum parasite
strains chosen on the basis of their global geographical origin and
invasion pathway preference. A striking concordance was observed
between the two antisera (IgG against 3D7 and W2mef EBA-175
RIII-V) in the pattern of GIA activity across these strains (Fig. 2
F&G), confirming that these antibodies neutralize parasite growth
in a strain-independent manner. To confirm that sequence
polymorphism did not affect GIA susceptibility, sequencing was
performed across RIII-V for all strains tested. No polymorphisms
were found within RIII sequences; 3D7, NF54, FCR3, BT3, TAK
994, FVO and CS2 were identical F-type alleles, and W2mef,
MCamp, HB3, Pf120, 7G8 and D10 were identical C-type alleles.
Within RIV-V, complete identity was found between W2mef and
3D7 and two identical amino acid changes found in all but one of
the other strains (Table S2). Overall, the limited variation across
strains in the target regions of the anti-EBA 175 RIII-V antibodies
likely determines the ability of serum against this antigen to confer
strain-independent growth inhibition. Furthermore, cross strain
inhibitory profiles of antibodies raised against dimorphic forms of
RIII-V indicated that the predominant growth inhibitory response
was likely directed to the conserved RIV-V region. RIV-V was
therefore expressed as a separate antigen and used to immunize
rabbits to determine whether this shorter, conserved domain could
induce cross-strain inhibitory antibodies. As predicted, IgG
targeting the EBA-175 conserved RIV-V was highly inhibitory
to parasite growth, with GIA ranging between 72–85% across
3D7, FCR3 and W2mef strains at 2 mg/ml (Figs. 2H). At
lower antibody concentrations, anti-RIV-V IgG was less inhibitory
than anti-RIII-V.













EBA-175 R3-5 (3D7) 1/1,280,000 16 9 30 ,16 17 Fig. 2A
EBA-175 R3-5 (W2mef) 1/2,560,000 8 37 45 60 47 Fig. 2C
EBA-175 F2-R5 (3D7) 1/2,560,000 8 56 85 50 64 Not shown
EBA-175 R4-5 (3D7) 1/2,560,000 8 198 250 175 208 Fig. 2H
EBA-140 R3-5 (3D7) 1/5,120,000 4 200 1250 1250 900 Fig. 4
EBA-175 R2 (3D7) 1/1,280,000 16 NA NA NA NA
PfRh2-NTR rbc binding 1/10,240,000 2 NA NA NA NA
PfRh2-2A9 CTR 1/5,120,000 4 NA NA NA NA
#IC50 values were calculated by interpolation on the plot of total IgG[log10] versus % GIA with measured points connected by straight lines (as described in [56],
calculations were performed on % GIA values in a 1-cycle assay, with IgG titrated from 2 mg/ml.
doi:10.1371/journal.pone.0072504.t001
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Figure 2. Epitopes of highly inhibitory, strain-transcending antibodies are located within the conserved region of EBA-175. (A) GIA
against the homologous 3D7 parasite strain. Rabbits were immunized with 3D7 EBA-175 region III-V. IgG purified from rabbit serum was serially
diluted from a starting concentration of 2 mg/ml. Data points indicate mean values of triplicate wells 6 standard error of the mean (SEM) in a single
Conserved Candidate Antigen for a Malaria Vaccine
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Parasite Invasion pathway switching does not affect
efficacy of growth inhibitory antibodies
Whilst IgG raised to EBA-175 RIII-V was inhibitory to parasite
strains that can use pathways other than EBA-175-Glycophorin A
to invade, (e.g. 3D7 parasites preferentially invade erythrocytes
using a sialic acid-independent pathway [46]), we were interested
in testing whether a parasite that had switched to an alternative
invasion pathway [47,48] could influence the efficacy of a vaccine-
induced immune response. We therefore tested a transgenic
parasite W2mef175-Cterm, in which the EBA-175 locus has been
modified and expresses an EBA-175 protein truncated 35 amino
acids upstream of the RV boundary. This has deleted the entire
region RIV, the trans-membrane and cytoplasmic domains, but
leaves region RIII-V of EBA-175 intact (Fig. 3A). Of note, these
parasites are no longer capable of invading erythrocytes using
EBA-175 and switch to a sialic acid independent pathway by
transcriptional activation of PfRh4 [7,47].
Immunoblot (Fig. 3A) and immunofluorescence microscopy
(Fig. 3B) confirmed that this truncated EBA-175 protein was
present in schizonts and merozoites, despite the loss of its C-
terminal end that includes transmembrane anchor and cytoplas-
mic tail. In wild type W2mef parasites (expressing full-length EBA-
175), immunofluorescence localization confirmed that EBA-175
co-localized with EBA-140 consistent with a micronemal location.
In W2mef175-Cterm parasites, however, the truncated EBA-175
protein consistently failed to co-localize with EBA-140, confirming
that RVI onwards encodes motifs that are essential for correct
subcellular trafficking of EBA-175 [49]. The truncated protein
frequently showed aberrant secretion during schizogony (Fig. 3B,
panel 3). Nevertheless, imaging of merozoites, including those
midway through invasion, showed that some EBA-175 was always
present in both W2mef and W2mef175-Cterm parasites during
invasion. Thus some truncated EBA-175 likely reaches the
micronemes, potentially evident in areas of low-level signal
coincidence between EBA-175 and EBA-140 in W2mef175-Cterm
schizonts (Fig. 3 B panel 4).
By GIA, IgG against 3D7 EBA-175 RIII-V inhibited invasion of
W2mef175-Cterm to the same level (80% inhibition) as W2mef
wild type parasites (Fig. 3C). This indicates that antibody efficacy
is unaffected by a switch in parasite invasion pathway usage or
expression of a truncated version of EBA-175. W2mefD175 KO
parasites, in which the entire eba-175 gene is deleted [46] were not
inhibited, further confirming antibody specificity for EBA-175.
EBA-140 RIII-V induces growth inhibitory antibodies
To explore whether targeting RIII-V in other functional
members of the PfEBA family of ligands had similar inhibitory
effects on parasite growth, we expressed the same region from
EBA-140, immunized rabbits and performed GIA against three P.
falciparum strains, as described for EBA-175. Again, 3D7 was the
strain most susceptible to IgG against EBA-140, with 80%
inhibition, with W2mef and FCR3 less so. Both strains, however,
still showed around 60% inhibition at 2 mg/ml IgG. Again, the
inhibition observed was specific to EBA-140, since there was no
effect against EBA-140 knockout parasites, or against D10, which
has lost the EBA-140 gene (Fig. 4). Thus RIII-V shows potent
inhibitory potential against two and potentially all EBL proteins.
High potency of IgG against conserved region of EBA
antigens
Having established the potency of anti-RIII-V serum by GIA,
we sought to select the best antigen partner for EBA-175 in an
invasion-blocking combination vaccine, and test other potential
EBA-175 candidate regions for suitability. Rabbit IgG from
immune sera against a panel of other parasite invasion ligands
(Fig. 1) were tested against 3D7, FCR3 and W2mef in GIA assays
at a concentration of 2 mg/ml. Of the four non-EBA-175
antigens, only EBA-140 antibodies were over 50% inhibitory
against all parasite strains (Fig. 5). The median % GIA across the
three parasite strains was calculated for each antibody and this
confirmed that antigens that included EBA-175 region IV-V
induced the highest inhibition levels. Median inhibition for anti-
EBA-140 RIII-V was lower than the EBA-175 antibodies, likely
due to the reduced efficacy of EBA-140 antibodies against
heterologous compared with homologous parasite strains, despite
complete sequence conservation. GIA levels for IgG raised against
the two PfRh2 antigens were similar to that found in previous
studies with around 20% inhibition against 3D7 parasites (Fig. S1).
The 3D7-EBA-175 knock-out line was the parasite strain most
susceptible to inhibition by IgG targeting PfRh2, confirming
previous findings that an additive or synergistic effect may be
found between antibodies targeting EBA-175 and PfRh2.
These data clearly demonstrate that of all blood stage antigens
tested in this study, EBA-175 region III-V performs best in a
comparative GIA across different parasite genotypes. To confirm
this finding, anti-EBA-175 RIII-V, anti-EBA175 RII and anti-Rh2
IgGs were tested independently in the GIA Reference Laboratory
at NIH using 3D7 parasites. While there was a difference in
absolute inhibition levels between the two sites, likely due to
differences in study methodology, anti-EBA-175 RIII-V clearly
out-performed anti-Region II antibodies, and anti-Rh2 N-terminal
antibodies were significantly more inhibitory to parasites than anti-
Rh2 C-terminal antibodies (Fig. 6).
An important consideration for vaccine efficacy against high
numbers of transiently exposed blood stage parasites is that
immunization should induce a potent antibody response. To
examine the potency of inhibitory IgG against EBA-175 antigens,
IC50 values were calculated. The numbers clearly show that not
only are antibodies against EBA-175 conserved regions highly
effective inhibitors of parasite growth at physiologically relevant
assay relative to pre-immune IgG, calculated from a 1-cycle FACS-based assay. The dashed red line indicates the IC50 value of IgG (9 mg/ml). (B)
Rabbit IgG against EBA-175 region III-V (3D7) – GIA against homologous and heterologous parasite strains. IgG from a single rabbit were tested
against 3D7, W2mef, FCR3 and 3D7D175 KO parasite strains. Data points represent mean values of triplicates from 3 independent replicate
experiments 6 SEM in a 2-cycle assay. The antibody is completely specific to EBA-175 as there is no inhibition of the 175-KO parasites. (C) Rabbit IgG
against EBA-175 region III-V (W2mef) – GIA against homologous and heterologous parasite strains. IgG from a single rabbit were tested against 3D7,
W2mef, FCR3 and 3D7D175 KO parasite strains (2 cycle assay). (D) Anti- EBA-175 RIII-V directly inhibit invasion of purified, viable, D10-GFP merozoites.
Results shown are mean + standard error of three independent experiments. (E) Mouse serum against EBA-175 region III-V (3D7) – GIA against
homologous and heterologous parasite strains. Three individual mouse sera were pooled and tested against 3D7, W2mef, FCR3 and 3D7D175 KO
parasite strains (1 cycle assay). (F) GIA patterns of Ig raised against both dimorphic alleles of EBA-175 against a panel of laboratory parasite strains are
highly correlated. GIA was performed in a one cycle assay using anti-EBA175RIII-V (3D7) IgG at a concentration of 1 mg/ml. Blue histograms indicate
parasite strains that invade predominantly via sialic-acid dependent pathway, red indicates sialic acid-independent pathway [63], grey bars where
invasion preference is not known. Parasite strains belonging to the C-type group are shown in blue font whereas those belonging to the F-type are
shown in red font. (G) GIA as for (F) but using anti-EBA175RIII-V (W2mef) IgG. (H) GIA using rabbit anti-EBA175 RIV-V (3D7) IgG (One-cycle assay).
doi:10.1371/journal.pone.0072504.g002
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IgG concentrations of 1–2 mg/ml, their activity remains high at
low concentrations (Table 1). EBA-175 RIII-V (3D7) IgG was the
most potent antibody tested with an average IC50 of 17 mg/ml
across the 3 strains in our laboratory under our particular
methodology.
Discussion
Development of a blood stage vaccine against malaria has been
hindered largely due to the high level of antigenic polymorphism
in the few target antigens that have made it to the clinic, resulting
in immune escape of parasites in both simian models [50] and
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Figure 3. EBA-175 inhibitory antibodies block merozoite invasion through receptors other than Glycophorin A. (A) Western blot of
post-invasion culture supernatants from W2mef and W2mef175-Cterm parasites probed with monoclonal antibody 9C4. This specifically recognizes
EBA-175 region III-V and shows the truncated form of the protein that includes RIII-V was present in W2mef175-Cterm parasites. (B) EBA-175 requires
motifs downstream of region 5 for correct trafficking within merozoites prior to invasion. Late segmented schizonts (ETS preparations) were co-
stained with antiserum against EBA-140 to detect micronemes (green), along with inhibitory mAb targeting EBA-175 (red). Indirect
immuofluorescence and phase contrast micrographs show correct co-localization within micronemes in wild type parasites (panels 1 &2) and
mis-localization of truncated EBA-175 protein in transgenic parasites, often with aberrant, early secretion (panels 3&4). Free and invading merozoites,
co-stained with the same W2mef-specific EBA-175 mAb (red) and RON4 to mark the tight junction (green), show that EBA-175 is present during
merozoite invasion in both wild type and transgenic parasites. In all cases nuclei are stained with DAPI (blue) and scale bars show 2 mm. (C) W2mef
and W2mef175-Cterm parasites were tested in GIA with IgG against EBA-175 RIII-V (3D7). Both parasite lines are inhibited equally efficiently by this
IgG, whereas no inhibition is seen against EBA-175 KO parasites (One-cycle assay).
doi:10.1371/journal.pone.0072504.g003
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clinical trials in human populations [51]. Results presented in this
paper show that the conserved region of EBA-175 induces potent,
parasite strain-independent, growth inhibitory antibodies that are
active at low IgG concentrations. Further, we confirmed that
antibodies raised against EBA-175 RIII-V inhibit merozoite
invasion directly, rather than inhibiting intracellular parasite
growth, in an inhibition of invasion assay using purified P.
falciparum merozoites. We propose that EBA-175 RIII-V should be
considered for further development as a component in a
combination malaria vaccine.
In this head to head comparison of EBA-175 antigens,
antibodies raised against RIII-V were more inhibitory to parasite
growth than those against RII, and this was confirmed by
independent testing at the GIA Reference Laboratory; although
the overall potency of the antibody inhibition for the region III-V
IgG was lower when tested there. One possible explanation for
discrepancy in antibody potency between the two labs could be
loss of antibody activity following freeze-thaw, since we have
subsequently experienced the same phenomenon (Healer et al
unpublished). This highlights the importance of standardized
methodology for these types of studies in the future. EBA-175 RII
induced weak growth-inhibitory antibodies against the homolo-
gous strain only, despite very good immunogenicity in rabbits. The
reason RII did not induce highly inhibitory antibodies is unclear.
One study that tested rabbit anti-RII antibodies in GIA reported
high levels of invasion inhibition [52], but subsequent studies
[32,53,54] report much lower levels of inhibition. This low level
GIA may however be improved by synergy with antibodies
targeting other merozoite antigens [55,56]. A possible explanation
for the differences in invasion inhibition of anti-RII IgG reported
by different studies could be that the antigen preparations are
expressed in different systems, and that protein folding, which is
critical for epitope recognition is slightly different between
different preparations. We confirmed that the RII antigen used
in this study bound to erythrocytes in a sialic-acid dependent
manner, which we assumed was indicative of correct structural
conformation. Support for a role for RII in naturally acquired
immunity to malaria is provided in a study of protective antibody
responses in a cohort of semi-immune children in Papua New
Guinea, which found a correlation between high levels of anti-
EBA-175 RII IgG and RIII-V IgG and delayed time to clinical
disease [12]. This however contrasted with previous studies in
Western Kenya [10,57] that found no association with antibody
level against EBA-175 RII and clinical protection. More
epidemiological studies, including a functional component, such as
GIA, are needed across different geographical sites and with a
range of antigens to further investigate such associations.
The testing of antibodies raised to two dimorphic alleles of
EBA-175 RIII-V indicated that dimorphic region III contributes
little to vaccine-induced immunity and conserved RIV-V contains
the predominant epitopes of inhibitory antibodies. The central
role of RIV-V in induction of functionally protective antibodies
was confirmed by comparably high GIA with anti-RIV-V, RIII-V
and F2-RV IgG. The F2-RV result also confirms that a
conformationally intact F2 domain is not necessary for the
induction of neutralizing antibodies targeting RIII-V. Why RIV-
V antibodies were less inhibitory than anti-RIII-V at lower
antibody concentrations is not understood. The end point IgG
concentration measured against the immunizing antigens was in a
similar range for both antibodies, however it was not possible to
directly measure the specific antibody titre against native parasite
protein, and it is a possibility that RIII when expressed in the
context of RIII-V contributes to the conformation of neutralizing
epitopes.
W2mef parasites were generally subject to lower levels of
inhibition across the lower range of antibody concentrations even
when the antibodies were generated with the W2mef RIII-V
protein. This was somewhat unexpected, since W2mef is known to
invade primarily via the EBA-175/Glycophorin A pathway, and


























Figure 4. Antibodies targeting region 3–5 of EBA-140 also
mediate cross-strain protection against P. falciparum. IgG
purified from immune rabbit serum was tested in GIA against 3D7,
W2mef and FCR3 strains. No inhibition was observed against EBA-140
knock out parasites. Highest GIA levels were against the homologous





























Figure 5. Summary of GIA data for antibodies tested against
three strains of P. falciparum. Data is represented as box and
whiskers plot; line represents the median inhibition of a particular
antibody against the three strains 3D7, FCR3 and W2mef; box,
interquartile range; and whiskers GIA minimum and maximum values.
Data included in the analysis are derived from triplicate wells in 3
independent, 2-cycle assays with IgG at a concentration of 2 mg/ml.
Anti-EBA-175 values in blue, anti-EBA-140 in purple and anti-Rh2

























Figure 6. Data from independent testing of rabbit IgG for GIA
activity. Data points indicate mean values of triplicate wells from a
single-cycle pfLDH-based assay using 3D7 parasites. % GIA was
calculated relative to pre-immune IgG.
doi:10.1371/journal.pone.0072504.g006
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antibodies. This effect is not due to an invasion pathway switch or
amino acid polymorphism. Possibly, EBA-175 protein concentra-
tion at the merozoite surface has some effect on susceptibility to
inhibition at lower antibody concentrations. Nonetheless, the
greater susceptibility of a supposedly sialic acid independent strain
(3D7) at low antibody concentration indicates that invasion
pathway preference does not determine susceptibility to anti-
body-mediated inhibition.
The high levels of polymorphism prevalent in RII, likely the
result of strong immune-mediated diversifying selection on this
erythrocyte binding region [29], may explain why antibodies
against this region do not inhibit heterologous parasite strains, and
this may contribute to the lack of association with protective
immunity in some cohort studies, depending on which strain the
antigen used in these studies originated from. In contrast, the high
degree of sequence conservation in RIV-V suggests that it may be
functionally constrained and therefore important for EBA-175
function or hidden from immune pressure to diversify. It is possible
that the dimorphic region III of EBA-175 may be immunologically
dominant, deflecting immune responses away from the function-
ally important RIV-V. Haplotype analysis of regions II, III and
IV-V in clinical isolates of P. falciparum will be important towards
determining whether other polymorphisms are present in field
isolates, and sero-epidemiological analyses to elucidate the relative
immunogenicity of these regions in malaria-exposed individuals
will be necessary to address these important questions.
Further evidence that RIV-V is a key domain in the function of
EBA proteins is clear from antibodies raised to the same region of
EBA-140, which are also inhibitory to parasite invasion. EBA-140
is not a functional invasion ligand in W2mef and FCR3 parasites
[58], which may explain the reduced susceptibility to anti-EBA140
antibodies by these parasite strains compared to 3D7. All three
strains are genetically identical in region III-V of EBA-140, ruling
out the possibility that strain-specificity is the reason for the
reduced susceptibility to antibody-mediated inhibition seen in
W2mef and FCR3. Naturally acquired antibodies to EBA-140 RII
and RIII-V were also associated with protective immunity in
children [12], strengthening the case for further vaccine-related
research on this antigen. These findings warrant more research
into the applicability of EBA-140 as a malaria vaccine candidate.
A recent paradigm for selection of vaccine candidates is that
target antigens should be essential to parasite development, and so
the ability to create in vitro genetic deletions of EBA-175 in two
laboratory isolates would appear to rule out this ligand as a good
vaccine candidate. In defense of EBA-175 however, there appears
to be strong selection maintaining the presence of this gene in wild
parasite populations, as it is the primary invasion ligand in many
endemic parasite isolates [59,60]. Expression levels of EBA-175
vary in lab and field isolates, but no parasite has been found in the
field that does not express EBA-175 and no correlation has been
found between varying expression level and invasion pathway
usage [61].
The diversity of ligand-receptor interactions employed by P.
falciparum provides a potential mechanism by which parasites
evade antigen-specific inhibitory immune responses, and this has
been demonstrated for antibodies targeting EBA-175 to some
extent by comparing wild type and EBA-175-null parasites to
demonstrate differences in susceptibility to naturally acquired
growth-inhibitory antibodies in malaria exposed children [11]. We
ruled out the possibility that vaccine induced antibodies targeting
EBA-175 RIII-V might be restricted to parasite strains using an
EBA-175 dependent, Glycophorin A invasion pathway, by using a
transgenic line which expresses an inactive, truncated EBA-175
protein to demonstrate that vaccine-induced IgG inhibit invasion
of this parasite strain as well as the wild type parasite. How this
truncated protein retains its presence at the merozoite surface
during invasion, despite some mis-localization compared to wild-
type protein during schizogony, is not yet apparent though it is
suggestive that EBA-175 may be part of a larger protein complex
that traffics it along with other adhesins to the point of merozoite
attachment with or without the cysteine-rich RVI domain.
Irrespective of this, it is clear that antibodies targeting EBA-175
prevent merozoite invasion of erythrocytes independently of EBA-
175/Gycophorin A pathway usage and despite the presence of
other ligands that are expressed and functional in these parasites.
Thus ligation of EBA-175 with an inhibitory antibody appears to
prevent invasion through other alternative adhesin-dependent
pathways. This finding was interesting in the light of data from an
elegant study that examined the dynamics of release of different
invasion ligands from apical organelles during merozoite invasion.
It revealed that the EBA proteins (175 and 140) were translocated
to the merozoite surface concurrently, and prior to exocytosis of
PfRh2b and another rhoptry protein CLAG 3.1. Furthermore, it
was found that receptor engagement by EBA-175 was required for
release of rhoptry proteins [62]. We speculate that antibodies
against EBA-175 RIII-V prevent release of rhoptry proteins
indirectly, perhaps through prevention of RII engagement with
glycophorin A.
The demonstration that growth inhibition by anti-EBA 175
antibodies is independent of invasion pathway is not novel, as
studies with antibodies targeting RII have shown similar effects
against strains using sialic-acid independent invasion [53,54]. The
levels of growth inhibition in those studies were, however, much
lower than found here. Crucially though, the potency of RIII-V
indicates that following vaccination with this antigen, the highly
inhibitory induced immune response would not be circumvented
by parasites switching invasion pathway. This indicates that
vaccination with this antigen is unlikely to drive immune escape by
mutation selection or switching invasion pathway since these
mechanisms would be unlikely to provide an adaptive advantage
to these parasites.
The finding that reconfiguring antigens by replacement of GST
with histidine tags for expression and purification appeared to
have a major effect on the production of inhibitory antibodies in
rabbits was surprising, and true in the case of both EBA-175 and
EBA-140 RIII-V, which had previously generated only mildly
inhibitory antibodies after multiple immunizations in rabbits. It is
possible that the larger GST tag may sterically mask neutralizing
epitopes in these particular antigens, or perhaps more likely, the
GST-tagged proteins used in earlier studies were not as
conformationally representative of the native antigen.
Although we observed up to 90% inhibition of parasite growth,
there was nonetheless variability between parasite strains in their
susceptibility to antibody-mediated inhibition. This emphasizes the
need to test many isolates in vaccine-related studies to gauge the
potential global efficacy of candidate antigens. Our present
findings indicate that EBA-175 RIII-V could be a key component
in a future malaria vaccine, but would not successfully prevent all
growth of all parasite strains. It has been suggested that an effective
blood stage vaccine should include more than one antigenic target
to cover potentially confounding effects of parasite phenotypic
diversity. Previously, we saw elevated GIA levels, indicative of a
synergistic effect on parasite growth when EBA-175 RIII-V was
co-immunized with PfRh2 [13]. It now becomes an imperative to
investigate the potentially synergistic interactions between anti-
bodies targeting EBA and PfRh proteins in co-immunization
studies towards full development of a strain-independent malaria
vaccine.
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Figure S1 Antibodies against PfRh2 N-terminal frag-
ment are superior to anti- C-terminal antibodies in GIA.
Rabbit IgG against PfRh2 antigens - GIA against homologous and
heterologous parasite strains. IgG raised against Rh2 N-terminal
fragment (A) and C-terminal fragment (B) were tested against 3D7,
W2mef, FCR3 and 3D7D175 KO parasite strains. Data points
represent mean values of triplicates from a 2-cycle assay.
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